Management to hold a conference call at 10:00 a.m. EDT
JERUSALEM--(BUSINESS WIRE)--May 15, 2014--
BioLineRx Ltd. (NASDAQ: BLRX)
(TASE: BLRX),
a clinical-stage biopharmaceutical company dedicated to identifying,
in-licensing and developing promising therapeutic candidates, announced
today that it will release its unaudited financial results for the
quarter ended March 31, 2014 on Tuesday, May 20, 2014, before the U.S.
markets open.
The Company will host a conference call on Tuesday, May 20 at 10:00 a.m.
EDT featuring remarks by Kinneret Savitsky, Ph.D., Chief Executive
Officer of BioLineRx, and Philip Serlin, Chief Financial and Operating
Officer of BioLineRx. A presentation will be provided on BioLineRx’s
website, to accompany management’s remarks on the conference call. The
conference call will be available via webcast and can be accessed
through the Investor Relations section of BioLineRx’s website, www.biolinerx.com.
Please allow extra time prior to the call to visit the site and download
any necessary software to listen to the live broadcast. To dial into the
conference call, please dial 1-888-860-9642 from the U.S. or
+972-3-918-0691 internationally.
A replay of the conference call will be available approximately two
hours after completion of the live conference call at www.biolinerx.com.
A dial-in replay of the call will be available until May 23, 2014;
please dial 1-888-276-1485 from the U.S. or +972-3-9255945
internationally.
About BioLineRx
BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company
dedicated to identifying, in-licensing and developing promising
therapeutic candidates. The Company in-licenses novel compounds
primarily from academic institutions and biotech companies based in
Israel, develops them through pre-clinical and/or clinical stages, and
then partners with pharmaceutical companies for advanced clinical
development and/or commercialization.
BioLineRx’s current portfolio consists of a variety of clinical and
pre-clinical projects, including: BL-1040 for prevention of pathological
cardiac remodeling following a myocardial infarction, which has been
out-licensed to Bellerophon BCM (f/k/a Ikaria) and is in the midst of a
pivotal CE-Mark registration trial; BL-8040 for treating acute myeloid
leukemia (AML) and other hematological indications, which is in the
midst of a Phase 2 study; and BL-7010 for celiac disease, which is in
the midst of a Phase 1/2 study.
For more information on BioLineRx, please visit www.biolinerx.com
or download the investor relations mobile device app, which allows users
access to the Company’s SEC documents, press releases, and events.
BioLineRx’s IR app is available on the iTunes App Store as well as the
Google Play Store.
Source: BioLineRx Ltd.
Tiberend
Strategic Advisors, Inc.
Joshua Drumm, Ph.D.
+1-212-375-2664
jdrumm@tiberend.com
or
Andrew
Mielach
+1-212-375-2694
amielach@tiberend.com
or
BioLineRx
Ltd.
Tsipi Haitovsky
Public Relations
+972-3-6240871
tsipihai5@gmail.com